Skip to main content
Evidence Snapshot

Glycine receptor subunit alpha-1

CHEMBL5845 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:16Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5845
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glycine receptor subunit alpha-1 as ChEMBL target CHEMBL5845, mapped to UniProt P23415. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glycine receptor subunit alpha-1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5845
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P23415
Glycine receptor subunit alpha-1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Glycine receptor subunit alpha-1 matters

As of 2026-09-13

Glycine receptor subunit alpha-1 is reviewed as Glycine receptor subunit alpha-1 (UniProt P23415); the current evidence base includes 13 approved drugs, 160 compounds, and 47 assays, with lead potency reaching pChEMBL 10.2.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 13 approved drugs, 160 compounds, and 47 assays for this target. The dominant activity type is IC50. CHEMBL4228372 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL4228372 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
13 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Glycine receptor subunit alpha-1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P23415, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

160
Total Compounds
47
Total Assays
13
Approved Drugs
IC50: 284.0, KI: 14.0, EC50: 40.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4228372
 10.2 EC50 —
No preferred name
CHEMBL5912281
 10.2 EC50 —
No preferred name
CHEMBL4227297
 9.4 EC50 —
No preferred name
CHEMBL6045267
 9.4 EC50 —
No preferred name
CHEMBL227934
 8.3 Ki —

Approved Drugs

Structure Compound First Approval
CINACALCET
CHEMBL1201284
 2004
DUTASTERIDE
CHEMBL1200969
 2001
CHOLECALCIFEROL
CHEMBL1042
 1999
RISPERIDONE
CHEMBL85
 1993
SULINDAC
CHEMBL15770
 1978
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:16Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5845